Key result
Concomitant therapy with r-hirudin and rTPA significantly reduced the incidence of residual macroscopic thrombus compared to heparin (28.6% vs 100%, P=0.01) in a porcine thrombosis model.
Why the study?
Does concomitant antithrombotic therapy (r-hirudin, heparin, or aspirin) improve thrombolysis and reduce residual thrombus when added to rTPA in a pig model of occlusive carotid thrombosis?
Population
29 pigs with occlusive platelet-rich thrombi formed in the carotid arteries by balloon dilatation followed…
Comparison
Recombinant tissue-type plasminogen activator… vs Placebo or rTPA alone
Design
Preclinical, allocated
Authors
Loading...
r-Hirudin plus rTPA merits further preclinical study; leaves open translation to human thrombolysis.
Does concomitant antithrombotic therapy (r-hirudin, heparin, or aspirin) improve thrombolysis and reduce residual thrombus when added to rTPA in a pig model of occlusive carotid thrombosis?
Absolute Event Rate: 28.6% vs 100%
p-value: p=.01
In a pig model of occlusive thrombosis, adding the direct thrombin inhibitor r-hirudin to rTPA significantly accelerated thrombolysis and reduced residual thrombus compared to heparin or aspirin.
Mruk et al. (1996) studied Occlusive platelet-rich thrombosis (n=29). rTPA plus r-hirudin vs. rTPA plus heparin, rTPA plus aspirin, rTPA alone, or placebo was evaluated on Incidence of residual macroscopic thrombus (p=.01). Concomitant therapy with r-hirudin and rTPA significantly reduced the incidence of residual macroscopic thrombus compared to heparin (28.6% vs 100%, P=0.01) in a porcine thrombosis model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: